| Literature DB >> 24753985 |
Anders Thomassen1, Anne Lerberg Nielsen1, Jeppe Kiilerich Lauridsen1, Björn Alexander Blomberg1, Søren Hess1, Henrik Petersen1, Allan Johansen1, Jon Thor Asmussen2, Jesper Roed Sørensen3, Jørgen Johansen4, Christian Godballe3, Poul Flemming Høilund-Carlsen1.
Abstract
The aim was to investigate the performance of (18)F-fluorodeoxyglucose PET/CT to rule out malignancy in patients with confirmed vocal cord palsy (VCP). Between January 2011 and June 2013, we retrospectively included consecutive patients referred to PET/CT with paresis or paralysis of one or both vocal cords. PET/CT results were compared to clinical workup and histopathology. The study comprised 65 patients (32 females) with a mean age of 66±12 years (range 37-89). Eleven patients (17%) had antecedent cancer. Twenty-seven (42%) were diagnosed with cancer during follow-up. The palsy was right-sided in 24 patients, left-sided in 37, and bilateral in 4. Median follow-up was 7 months (interquartile range 4-11 months). Patients without cancer were followed for at least three months. PET/CT suggested a malignancy in 35 patients (27 true positives, 8 false positives) and showed none in 30 (30 true negatives, 0 false negatives). Thus, the sensitivity, specificity, positive and negative predictive values, and accuracy were (95% confidence intervals in parenthesis): 100% (88%-100%), 79% (64%-89%), 77% (61%-88%), 100% (89%-100%), and 88% (78%-94%), respectively. Sixteen patients had palliative treatment, while 11 were treated with curative intent, emphasising the severity of VCP and the need for a rapid and accurate diagnostic work-up. In this retrospective survey, biopsy proven malignancy (whether newly diagnosed or relapsed) was the cause of VCP in almost half of patients (42%). PET/CT had a high sensitivity (100%) with a relatively high false positive rate, but was excellent in ruling out malignancy (negative predictive value 100%).Entities:
Keywords: FDG-PET/CT; laryngeal nerve; palsy; paralysis; paresis; vocal cord
Year: 2014 PMID: 24753985 PMCID: PMC3992212
Source DB: PubMed Journal: Am J Nucl Med Mol Imaging